Loading…
← CockpitCompetitor Analysis › APTX.TO Apotex Health Corp.Open in the cockpit ↗

Apotex Health Corp.APTX.TOCompetitor analysis, valuation and peers

Canada · CAD·Health Care›Pharmaceuticals: Major

Toronto-based generic, biosimilar and consumer-health pharmaceutical maker, the largest Canadian-headquartered pharma company, recently listed on the TSX.

≈ Canada's Teva/Viatris
Mkt cap
$6.56B
US dollars, full cap
Free float
41%
of shares outstanding
$/day
$10.4M
20-day average traded
Fwd P/E
19.3×
forward earnings
ROIC−WACC
+19.9 pp
WACC 5.1%
Hurdle
-16 pp
Req g minus delivered
Next earnings
105 days
3 Mar 2027
Close · CADC$41.17
1D+3.1%
1W+14.4%
1M+26.7%
3M+20.1%
6Mn/a
YTDn/a
1Yn/a
ATR %2.8%
52w lowhigh0.1% off high

What Apotex Health does

Toronto-based generic, biosimilar and consumer-health pharmaceutical maker, the largest Canadian-headquartered pharma company, recently listed on the TSX.

In one line: Canada's Teva/Viatris.

Products and services

  • Generic prescription drugs
  • Biosimilars
  • Consumer health/OTC products
  • Active pharmaceutical ingredients

Customers

  • Pharmacy chains/distributors (Canada, US, internat
  • Hospitals
  • Health systems

Where it sits in the supply chain

  • Pharmaceuticals
  • Generic and biosimilar drug…
  • Branded + consumer health products

What could go right

  • Biosimilar patent-expiry launches
  • Post-IPO capital funding growth investments

What could go wrong

  • Generic drug price erosion
  • Regulatory/manufacturing compliance risk

Moat: narrow (scale, regulatory licence). Largest Canadian pharma manufacturing scale and a broad portfolio of regulatory-approved generic/biosimilar filings.

Headquarters: Toronto, Canada · Founded: 1974 · Employees: 6,216

Named competitors

Apotex Health at a glance

Size Apotex Health (APTX.TO) is a Canada Health Care company (Pharmaceuticals: Major) with a market value of $6.56B, the 95th largest of 405 Canada companies the cockpit tracks. Shares closed at C$41.17 on 18 Nov 2026.

Growth Revenue grew 4.2% over the last twelve months (peer median +16.4%); the operating margin is 32.0% (peer median 13.8%).

Valuation It trades at 19.3× forward earnings against a peer median of 24.1× (7th cheapest of 15).

Price implies For today's price to make sense, revenue must grow about -12% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -16 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 19.9 points above its cost of capital (5.1% WACC).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Apotex Health financials

Reported figures in CAD; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023
Revenuen/aC$3.49BC$3.35BC$2.94B
Revenue growth—+4%+14%—
Gross profitn/aC$1.83BC$1.70BC$1.05B
EBITDAn/aC$1.27BC$1.13BC$563M
Net incomen/aC$374MC$152M-C$147M
Free cash flown/aC$520MC$461MC$475M
Capital expendituren/aC$182MC$244MC$112M
Total debtC$2.94BC$3.52BC$2.65BC$1.87B

Quarterly statements and history in the cockpit →

Apotex Health competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Fundamentals: revenue growth against valuation

0%+100%+200%20×40×60×000999ALKEM000963BIOCON688331BANB6821SUPN4528CORTKNSAAPTX.TORevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Apotex Health is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%100%200%300%000999ALKEM000963688331SUPNLGNDKNSAAPTX.TOGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Apotex Health is the large dot.

Apotex Health competitors and peer comparison

Head to head with its named competitors (APTX.TO vs TEVA vs VTRS vs SDZ.SW)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Apotex Health APTX.TO$6.56Bn/a+4%32%19.3×-11.9%
Teva Pharmaceutical Industries Limited Sponsored ADR TEVA$49.3B+23%-4%19%15.0×10.5%
Viatris VTRS$23.3B+23%+5%11%7.5×11.2%
Sandoz SDZ.SW$41.7B+26%+1%15%24.5×7.5%

How Apotex Health compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Apotex Health against its 20 peers (data as of 18 Nov 2026)
MeasureAPTX.TOPeer medianRank in peer set
1-month return+26.7%-2.1%highest of 21
Distance from 52-week high-0.1%-25.4%highest of 21
Revenue growth (TTM)+4.2%+16.4%5th lowest of 18
Operating margin32.0%13.8%3rd highest of 19
Forward P/E19.3×24.1×7th cheapest of 15
Growth the price implies (Req g, 7 yrs)-11.9%7.1%least demanding of 11
Growth delivered (Del g)+4.2%+12.3%lowest of 11
Hurdle (Req g minus delivered)-16.1 pp-8.4 pp5th least demanding of 11
ROIC minus cost of capital+19.9 pp+1.9 pp4th highest of 18
EV / EBITDA9.7×25.5×2nd cheapest of 10
Net debt / EBITDA2.3×0.3×3rd most indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Apotex Health APTX.TOCanada$6.56Bn/a+4%32%19.3×-11.9%+4.2%
China Resources Sanjiu Medical & Pharmaceutical 000999.SZChina$6.59B+6%+4%14%13.2×-6.2%+18.4%
Oruka Therapeutics ORKAUnited States$6.49B+58%n/an/an/an/an/a
Samsung Epis 0126Z0.KSSouth Korea$6.49B-31%n/a12%23.8×n/an/a
Alkem Laboratories ALKEM.NSIndia$6.69B-5%+13%17%27.3×25.0%+10.7%
Huadong Medicine 000963.SZChina$6.69B-18%+2%9%12.5×-3.9%+5.3%
Belite Bio, Inc. ADR BLTEUnited States$6.41B+9%n/an/an/an/an/a
Biocon BIOCON.NSIndia$6.31B-15%+6%8%61.3×n/an/a
RemeGen 688331.SSChina$6.28B-24%+272%61%10.8×1.1%+303.3%
Akeso 9926.HKHong Kong$7.01B-48%+42%-25%n/an/an/a
Bachem BANB.SWSwitzerland$7.06B0%+5%19%32.4×n/an/a
Asymchem Laboratories (Tianjin) 6821.HKHong Kong$7.10B+17%+24%17%24.4×n/an/a
ImmunityBio IBRXUnited States$7.13B-17%+121%-150%n/an/an/a
Mirum Pharmaceuticals MIRMUnited States$6.04B-5%+42%-21%n/an/an/a
Cytokinetics CYTKUnited States$7.15B-35%+30%-625%n/an/an/a
Supernus Pharmaceuticals SUPNUnited States$6.02B-41%+16%45%8.0×6.2%+13.9%
Ligand Pharmaceuticals LGNDUnited States$5.98B+37%+1%14%27.3×57.7%+7.5%
ONO Pharmaceutical 4528.TJapan$7.33B-2%-2%22%15.3×-6.8%+10.8%
Corcept Therapeutics CORTUnited States$7.42B+15%+30%12%15.3×23.9%+16.6%
Abbott India ABBOTINDIA.NSIndia$5.80B-8%+7%28%31.1×8.0%+10.0%
Kiniksa Pharmaceuticals International KNSAUnited States$7.47B+75%+58%14%56.6×10.4%+45.5%

Questions

Who are Apotex Health's main competitors?
Named competitors: Teva Pharmaceutical (TEVA), Viatris (VTRS), Sandoz Group (SDZ.SW). The cockpit's measured peer set (industry) also includes China Resources Sanjiu Medical & Pharmaceutical (000999.SZ), Oruka Therapeutics (ORKA), Samsung Epis (0126Z0.KS), Alkem Laboratories (ALKEM.NS), Huadong Medicine (000963.SZ), Belite Bio, Inc. ADR (BLTE).
Is Apotex Health expensive compared with its peers?
On forward p/e it trades at 19.3× against a peer median of 24.1×, 7th cheapest of 15 in its peer set. For today's price to make sense, revenue must grow about -12% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -16 pp: the price already allows for a slowdown.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.